MarketPeel
Insider Trading Intelligence
ST

Sharon Townson

GLUE
CHIEF SCIENTIFIC OFFICER · MONTE ROSA THERAPEUTICS, INC. · CIK 0001855689
FILING MIX · LIFETIME59%/41%
BUYS
10
SELLS
7
TOTAL VALUE
$357.8K
COMPANIES
1
ACTIVE SINCE
Mar 2022
HOLDINGS NOW
70,845
AVG SELL PX
$18.75
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Sharon Townson, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+64.72%+1.08%+63.64%+63.64%
14d1+0.00%+69.72%-1.47%+71.20%+71.20%
30d1+0.00%+35.63%-0.22%+35.85%+35.85%
60d1+0.00%+23.61%-2.23%+25.84%+25.84%
90d1+0.00%+17.57%-4.19%+21.76%+21.76%
180d1+0.00%+68.13%+8.30%+59.83%+59.83%
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
GLUE · 70,845 shares · as of Jun 23, 2026
052,323104,645156,968209,2902023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 10 buys / 7 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
3,000$6.14$18.4K70,845Jun 23, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,000$20.00$60.0K67,845Jun 23, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
3,000203,290Jun 23, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,000$19.00$57.0K67,845Jun 17, 2026Jun 18, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
3,000206,290Jun 17, 2026Jun 18, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
3,000$6.14$18.4K70,845Jun 17, 2026Jun 18, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
6,000$6.14$36.8K73,845May 29, 2026Jun 1, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,000$19.87$119.2K67,845May 29, 2026Jun 1, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
6,000209,290May 29, 2026Jun 1, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Scientific Officer
3,155$15.17$47.9K67,845Jan 5, 2026Jan 5, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,00071,000Jan 2, 2026Jan 5, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
158,000158,000Jan 2, 2026Jan 5, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
161,000161,000Jan 2, 2025Jan 6, 2025View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,00036,000Jan 2, 2025Jan 6, 2025View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,00040,000Jun 3, 2024Jun 5, 2024View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
78,55078,550Jan 3, 2023Jan 4, 2023View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,00070,000Mar 1, 2022Mar 2, 2022View →
Other insiders · GLUE
Loading peer insiders…
About this filer
CIK 0001855689
ROLE
Chief Scientific Officer
PRIMARY
GLUE
COMPANIES
1
ACTIVE SINCE
Mar 2022
MARKETPEEL · /INSIDER/0001855689DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback